Q1 2019 13F Holders as of 31 Mar 2019
-
Type / Class
-
Debt / NOTE 2.000% 8/1
-
Number of holders
-
11
-
Total 13F principal, excl. options
-
275,922,000
-
Principal change
-
-26,000,000
-
Total reported value, excl. options
-
$195,651,000
-
Value change
-
-$21,007,000
-
Number of buys
-
1
-
Number of sells
-
-2
-
Price
-
$0.6825
Significant Holders of AEGERION PHARMACEUTICALS INC - NOTE 2.000% 8/1 as of Q1 2019
13 filings reported holding 00767EAB8 - AEGERION PHARMACEUTICALS INC - NOTE 2.000% 8/1 as of Q1 2019.
AEGERION PHARMACEUTICALS INC - NOTE 2.000% 8/1 has 11 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $275,922,000 of principal
.
Largest 10 bondholders include Athyrium Capital Management, LP ($117,737,000 of principal), EdgePoint Investment Group Inc. ($52,392,000 of principal), HIGHBRIDGE CAPITAL MANAGEMENT LLC ($52,100,000 of principal), Allianz Asset Management GmbH ($20,980,000 of principal), AMERIPRISE FINANCIAL INC ($12,460,000 of principal), Stonepine Capital Management, LLC ($9,000,000 of principal), Whitebox Advisors LLC ($7,200,000 of principal), ORBIMED ADVISORS LLC ($2,000,000 of principal), Context Capital Management, LLC ($1,500,000 of principal), and BlackRock Inc. ($550,000 of principal).
This table shows the top 11 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.